Acadia Pharmaceuticals | ACAD - 销售和管理费用

金融业

USD

USD 1.61B

现金及等价物

USD 851.46M

USD 24.79M

USD 1.1B

USD 305.52M

USD 52.19M

USD -4.62M

USD 20.32M

653

EPS每股收益

USD 0.02

股本和储备

USD 1.25B

USD 243.27M

债务利息支出

USD 0

USD 8.33M

USD 0

USD 4.13B

USD 3.64M

USD 272.68M

USD -4.62M

普通股股本

USD 169.18M

10.08

USD 3.98M

USD 268.06M

销售和管理费用

USD 160.79M

USD 31.57M

贸易债权人

USD 12.25M

应收帐款人

USD 148.38M

	销售和管理费用	更改		日
Acadia Pharmaceuticals	USD 160.79M		14.06M	2026-03
ALKERMES	USD 264.59M		77.4M	2026-03
Alnylam Pharmaceuticals	USD 282.51M		2.55M	2026-03
Biogen	USD 554.3M		128.2M	2026-03
BioMarin Pharmaceutical	USD 258.28M		63.92M	2026-03
Bristol-Myers Squibb	USD 1.62B		564M	2026-03
Cara Therapeutics	USD 2.19M		2.45M	2025-09
Corcept Therapeutics	USD 128.04M		13.3M	2026-03
Cytokinetics	USD 104.9M		13.17M	2026-03
Eisai	JPY 119.54B		7.82B	2026-03
Eli Lilly	USD 2.93B		198M	2026-03
Incyte	USD 328.1M		62.31M	2026-03
J&J	USD 6.42B		381M	2026-06
Moderna	USD 173M		135M	2026-03
Neurocrine Biosciences	USD 318.5M		16.7M	2026-03
Pfizer	USD 2.92B		1.16B	2026-03
Prothena	USD 12.67M		5.02M	2026-03
PTC Therapeutics	USD 73.89M		13.31M	2026-03
Sarepta Therapeutics	USD 54.03M		51.35M	2026-03
Ultragenyx Pharmaceutical	USD 88M		1000K	2026-03
Vanda Pharmaceuticals	USD 39.28M		1.71M	2024-12
Vertex Pharmaceuticals	USD 493.7M		6.7M	2026-03